

ASX ANNOUNCEMENT

Appendix 4C – Quarterly Cash Flow Report

Highlights for the quarter ended 30th June 2021

- **US Patent granted for PeriCoach motion sensors**
- **Quality control and Assurance systems near completion**
- **\$3.82M Capital raising completed**
- **Enhanced Infusion System Middle East distribution agreement**

30th July 2021: Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach® system and the Enhanced Infusion System technologies, has today released its Appendix 4C - Quarterly Cashflow report for the period ending 30th June 2021.

On the 30th April, Analytica was pleased to announce the granting of US patent 10,966,654 "Intra vaginal device to aid in training and determining muscle strength" concerning the use of motion sensors in pelvic floor exercise devices. The patent was granted on the 6th April 2021 and will expire on the 16th October 2035 provided all renewal fees are paid.

The US is the biggest medical device market in the world, and this patent gives Analytica a level of intellectual property protection in the market for the pelvic floor exercise technique features of the PeriCoach system.

The PeriCoach technique feedback functionality uses inputs from the uniquely positioned PeriCoach force sensors, whose invention is described in a separate patent family, and movement sensors to assess the technique used to contract the pelvic floor muscles. This information is presented to the patient as she does her exercise via the PeriCoach app. Analytica's real-world data from paying patients shows that 57% of women don't engage their pelvic floor muscles correctly when they first start pelvic floor exercise. With the real-time biofeedback provided by PeriCoach, they are able to correct their contraction technique.

This invention has also been granted patent protection in Australia. Analytica also has patent protection granted for the PeriCoach for sensor orientation in Australia, China and Japan. Both patent families have applications pending in other jurisdictions such as Europe.

A major project restructuring the quality control and quality assurance for the PeriCoach to enable certification of an in-house manufacturing facility is almost completed. This project is complex and consumed considerable resources to enable Analytica to take control of our production rather than rely on contract manufacturers. It is anticipated auditing of the systems will be completed in the next quarter.

On the 23rd April Analytica Ltd announced a share placement at an issue price of 0.35 cents per share to raise up to \$3.82 million subject to shareholder approval (**Placement**).

This capital allows Analytica to pursue opportunities for both PeriCoach and EIS in foreign and domestic markets, particularly North America and Europe, adding to the existing manufacturing and distribution agreements announced for China and the Middle East.



Extraordinary General meeting was held on the 18th June where shareholders approved, under the Placement:

- 879,903,083 new shares (**New Shares**) issued to institutional and sophisticated investors and other persons to whom no disclosure is required under the Corporations Act 2001 (Cth);
- 879,903,083 attaching options with an exercise price of 0.5 expiring on the 18th June 2023 to institutional and sophisticated investors and other persons to whom no disclosure is required under the Corporations Act 2001 (Cth)
- 214,285,714 placement shares and 214,285,714 attaching options with an exercise price of 0.5 cents per option , expiring on the 18th June 2023 issued to nominee of Dr Monsour,
- 25,000,000 options with an exercise price of 0.5 cents per option expiring on the 18th June 2023 (Broker Options) issued to 180 Markets Pty Ltd
- 50,000,000 options with an exercise price of .05 per option expiring on the 23rd June 2023 issued to nominee of Ross Mangelsdorf

On the 20th April Analytica, entered into an agreement with an Egyptian entity, Marwa's Office for Export & Import Medical Supplies to distribute and market the EIS in Egypt, Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Saudi Arabia and United Arab Emirates (Licensed Territory). Marwa's Office for Export & Import Medical Supplies is based in Tanta, Egypt.

The Egyptian public/parastatal sector consists of quasi-governmental organizations such as the Health Insurance Organization and the Curative Care Organization. Principals of Marwa's Office for Export & Import Medical Supplies have extensive experience of the Egyptian health system, as a consultant and undersecretary of health for the Egyptian Health Insurance Organization Clinics (HIO) as well as leadership positions in the Egyptian Ministry of Health.

Subject to Egyptian Ministry of Health clearance, the plan is to distribute the EIS through the hospital network in Egypt. Egypt with a population of over 100 million people has 1,848 hospitals with more than 131,000 beds. Egypt's medical device market is the second largest in the Middle East. The Egyptian government is rapidly improving the health system and has introduced the Universal Health Insurance Law to provide a comprehensive health insurance system all over Egypt which the Egyptian government is aiming to cover all Egyptians by the year 2025.

The Enhanced Infusion System (EIS) is a simple and inexpensive solution to reduce monitoring costs and automatically restart flow after medication delivery during intravenous fluid infusion.

The agreement furthers Analytica's strategy to bring the EIS and PeriCoach into global markets, building upon the PeriCoach agreement for the Middle East with partner Motion Egypt LLC, and the recently announced agreement with Nacol for PeriCoach in China, Macau, Hong Kong and Taiwan, as well as pursuit of other partners in North America, Europe and Southeast Asia outside of China.

Costs have been reviewed and tightened to ensure progress with development and finalise negotiations. With the signing of these agreements costs will be incurred for regulatory and legal as well as deployment of technology.

The Company at the 30th June 2021 had cash of \$1.89 million and repaid outstanding loan from the unsecured revolving working capital facility for up to \$1.5 million from Halonna Pty Ltd, an entity associated with the Chairman, Dr Michael Monsour (**Facility**). Interest was payable at a commercial unsecured



overdraft rate, presently 8.51%, quarterly in arrears. The Facility was to be repaid in full on the earliest of 30 June 2021, completion of an equity raising of more than \$250,000 and 14 days after a change of control event¹ occurs in relation to the Company, which has occurred.

Halonna Pty Ltd has agreed to continue to provide a loan facility up to \$400,000 on the same terms with extension date to 30th June 2022.

Aggregate payments to related parties and their associates amounted to \$422k which included payment of outstanding directors fees which had not been paid since March 2020.

Authorised for release by the Board.

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance for urinary incontinence in Australia and has CE mark and USFDA 510(k) clearance.

PeriCoach also has clearance in Australia, and CE Marking in Europe for the treatment of pelvic organ prolapse, a condition that affects up to 1 in 5 women during their lifetime.



¹ A change of control occurs if (a) any person, whether alone together with the person's associates (other than the Halonna and its associates), acquires a relevant interest in 20% or more of the issued share capital of Analytica or (b) a person (either alone or with that person's associates) who was unable to control the composition of Analytica's Board as at the date of this document, acquires that ability.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

ANALYTICA LTD

ABN

12 006 464 866

Quarter ended ("current quarter")

Jun 2021

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	4	4
1.2 Payments for		
(a) research and development	(56)	(607)
(b) product manufacturing and operating costs	(2)	(12)
(c) advertising and marketing	(109)	(174)
(d) leased assets		
(e) staff costs	(437)	(976)
(f) administration and corporate costs	(204)	(633)
1.3 Dividends received (see note 3)		
1.4 Interest received		
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives	4	788
1.8 Other (provide details if material)		7
1.9 Net cash from / (used in) operating activities	(800)	(1,603)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities		
(b) businesses		
(c) property, plant and equipment	(1)	(4)
(d) investments		
(e) intellectual property		
(f) other non-current assets		

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	Net cash from / (used in) investing activities	(1)	(4)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	3,829	3829
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities		
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings	(1,136)	(133)
3.7	Transaction costs related to loans and borrowings	(264)	(264)
3.8	Dividends paid		
3.9	Other (provide details if material)		
3.10	Net cash from / (used in) financing activities	2,429	3,432

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	263	66
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(800)	(1,603)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(1)	(4)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	2,429	3,432
4.5	Effect of movement in exchange rates on cash held		
4.6	Cash and cash equivalents at end of period	1,891	1,891

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,891	263
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,891	263

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	422
6.2	Aggregate amount of payments to related parties and their associates included in item 2	
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	400	
7.2	Credit standby arrangements		
7.3	Other (please specify)		
7.4	Total financing facilities	400	
7.5	Unused financing facilities available at quarter end		400
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	An unsecured revolving working capital facility for up to \$400k from Halonna Pty Ltd, an entity associated with the Chairman, Dr Michael Monsour (Facility). Interest is payable at a commercial unsecured overdraft rate, presently 8.51%, quarterly in arrears. The Facility must be repaid in full on the earliest of 30 June 2022, completion of an equity raising of more than \$250,000 and 14 days after a change of control event occurs in relation to the Company.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(800)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,891
8.3	Unused finance facilities available at quarter end (item 7.5)	400
8.4	Total available funding (item 8.2 + item 8.3)	2,291
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	2.8
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer:	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer:	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer:	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: ...30/7/2021.....

Authorised by:Ross Mangelsdorf.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.